Private Funding Seen as Catalyst for India's Biotech Innovation Pipeline
In a statement released on Monday, Dr. Jitendra Singh emphasized that boosting private investment is essential for propelling India’s biotechnology sector onto the world stage. He argued that indigenous biotech solutions must receive strong industry endorsement and financial support to move swiftly from research labs to commercial markets.
The minister’s remarks came after a detailed briefing with senior BIRAC officials. He underlined the importance of a coordinated approach among scientists, manufacturers, and capital providers to ensure rapid commercial success for new technologies.
Among the initiatives reviewed were the BIRAC‑RDF, intended to allocate a substantial share of the ₹1 lakh crore national R&D budget to high‑risk, deep‑tech biotech projects. Eligible ventures may secure funding between ₹5 crore and ₹200 crore, with up to half of the project cost financed via flexible, non‑secured loan and equity structures.
The minister also highlighted plans to integrate India’s more than 1,700 Global Capability Centers (GCCs) – which employ roughly 1.9 million professionals – with home‑grown biotech incubators, bio‑foundries and start‑ups, creating a collaborative platform for technology transfer and joint ventures.
Furthermore, Dr. Singh endorsed the use of CSR capital for biotech‑driven social innovations, targeting affordable healthcare, diagnostics, maternal‑child health, nutrition, climate‑smart agriculture and skill development.
A dedicated “BIRAC Startup Investor Connect” portal will bring investors and ready‑to‑scale biotech start‑ups together, accelerating partnership formation and product launch timelines.
These steps are designed to fast‑track Indian inventions from bench to market, contributing to the broader goal of a self‑sufficient, internationally competitive biotech landscape by 2047.